ECRAID-Base: European Clinical Research Alliance on Infectious Diseases
ECRAID-Base aims to establish a long-term, self-sustainable Pan-European clinical research network.
This infrastructure would advance research in developing new diagnostic, preventive, and therapeutic strategies for managing infectious diseases. It will also facilitate in delivering much faster, more efficient and cost-effective clinical research against emerging infectious diseases (EID) and antimicrobial resistance (AMR).
Participant Information Documents
Funding: European Union’s Horizon 2020 research and innovation programme
Sponsor: University Medical Center Utrecht (UMCU), the Netherlands
Background and Study Aims
Currently, there is a lack of international collaboration, resulting in fragmentation and isolation of research efforts, inefficient use of scarce research resources, and suboptimal response to infectious diseases.
Therefore, this perpetual Observational study will help generate rigorous evidence to improve the diagnosis, prevention, and treatment of infectious diseases. The infrastructure would be equipped to respond to public health threats effectively and rapidly through the collaboration of many different European countries and industry partners.
Who can participate?
Participants aged 60 years and over registered with their GP practice can take part in this study if they are experiencing symptoms of an Acute Respiratory Infection (ARI).
POS-ARI-PC AUDIT: Netherlands, France, Norway, Hungary, Denmark, UK, Poland, Ireland, Belgium, Greece, Spain, Armenia, Moldova, Georgia, Croatia, Sweden, Switzerland.
POS-ARI-PC CORE: TBC
What does the study involve?
The participants will be enrolled at participating GP practices across Europe when they present with symptoms of an acute respiratory infection. A baseline assessment would be completed and a combined throat and nose swab will be taken for study purposes. During the course of the study, participants will also need to complete an online/paper diary for 14 days.
Participants may also be invited for a qualitative interview that is entirely optional. This is to better understand their overall experience of taking part and their perspectives on this study.
What are the possible risks and benefits of participating?
No risks to participants taking part in this study.
Participants may not personally benefit from taking part but will help inform researchers and doctors in identifying best practices for the diagnosis and management of acute respiratory tract infections. Thereby they are potentially helping society as a whole, not just their country, but also Europe and possibly the world.
Zaeck, L.M., Lamers, M.M., Verstrepen, B.E. et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med 29, 270–278 (2023). https://doi.org/10.1038/s41591-022-02090-w
Hassoun-Kheir N, van Werkhoven CH, Dunning J, Jaenisch T, van Beek J, Bielicki J, Butler CC, Francois B, Harbarth S, Hernandez Padilla AC, Horby P, Koopmans M, Lee J, Rodriguez-Baño J, Tacconelli E, Themistocleous Y, van der Velden AW, Bonten M, Goossens H, de Kraker MEA; ECRAID-Base consortium. Perpetual observational studies: new strategies to support efficient implementation of observational studies and randomized trials in infectious diseases. Clin Microbiol Infect. 2022 Dec;28(12):1528-1532. doi: 10.1016/j.cmi.2022.07.024. Epub 2022 Aug 5. PMID: 35940566; PMCID: PMC9354481.
van Beek Janko, Fraaij Pieter LA, Giaquinto Carlo, Shingadia Delane, Horby Peter, Indolfi Giuseppe, Koopmans Marion, Acute hepatitis study group. Case numbers of acute hepatitis of unknown aetiology among children in 24 countries up to 18 April 2022 compared to the previous 5 years. Euro Surveill. 2022;27(19):pii=2200370. https://doi.org/10.2807/1560-7917.ES.2022.27.19.2200370